POLYMED Stock Overview
Manufactures and sells medical devices in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Poly Medicure Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,607.70 |
| 52 Week High | ₹3,357.80 |
| 52 Week Low | ₹1,361.00 |
| Beta | 0.34 |
| 11 Month Change | 6.33% |
| 3 Month Change | 19.45% |
| 1 Year Change | 71.67% |
| 33 Year Change | 173.47% |
| 5 Year Change | 1,160.37% |
| Change since IPO | 7,162.52% |
Recent News & Updates
Recent updates
Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge
Nov 02
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being
Sep 20Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00
Sep 14After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar
Sep 06Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet
Aug 14Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138
Jul 27Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)
Jul 11Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations
May 25Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital
May 12Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up
Mar 23Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today
Feb 15Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly
Jan 16Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?
Nov 14Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward
Oct 24Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being
Sep 22Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00
Sep 08Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly
Aug 12Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching
Jul 13Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return
Jun 16Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital
Mar 02We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt
Feb 14Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal
Oct 16We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt
Sep 28Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50
Sep 08Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly
Jun 25A Look At The Intrinsic Value Of Poly Medicure Limited (NSE:POLYMED)
Jun 07Poly Medicure (NSE:POLYMED) Will Want To Turn Around Its Return Trends
May 23With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting
Feb 23There Are Reasons To Feel Uneasy About Poly Medicure's (NSE:POLYMED) Returns On Capital
Feb 04Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly
Jan 12With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting
Oct 14Poly Medicure (NSE:POLYMED) Could Easily Take On More Debt
Jul 07Poly Medicure (NSE:POLYMED) Will Will Want To Turn Around Its Return Trends
Jun 18Poly Medicure's (NSE:POLYMED) Solid Profits Have Weak Fundamentals
May 31Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹1,195
May 26Shareholder Returns
| POLYMED | IN Medical Equipment | IN Market | |
|---|---|---|---|
| 7D | -3.8% | -3.7% | -1.8% |
| 1Y | 71.7% | 65.7% | 27.2% |
Return vs Industry: POLYMED exceeded the Indian Medical Equipment industry which returned 63.5% over the past year.
Return vs Market: POLYMED exceeded the Indian Market which returned 27% over the past year.
Price Volatility
| POLYMED volatility | |
|---|---|
| POLYMED Average Weekly Movement | 6.3% |
| Medical Equipment Industry Average Movement | 6.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: POLYMED has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: POLYMED's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 6,300 | Himanshu Baid | www.polymedicure.com |
Poly Medicure Limited manufactures and sells medical devices in India and internationally. It offers infusion devices, such as I.V. cannulas, mid line catheters, arterial cannula, three way stop cocks, I.V. infusion sets, manifolds, safety winged infusion sets, T-type extension sets, stylet/mandrin with luer locks, vial access spikes, measured volume fluid administration sets, extension lines, central venous catheters, CVP manometers, needle free connectors, pre filled syringes, vascular accesses, and blood administration sets. The company also provides nasogastric and infant feeding tubes, gastro-duodenal feeding tubes, and umbilical catheters; urine collection bags, foley balloon catheters, irrigation sets, urine drainage catheters, and urine collection bags with measured volume meters; and endotracheal and tracheostomy tubes, mucus extractors, ventilator circuits, bain circuits, catheter mounts, spinal needles, HME filters, and laryngeal mask airways.
Poly Medicure Limited Fundamentals Summary
| POLYMED fundamental statistics | |
|---|---|
| Market cap | ₹263.78b |
| Earnings (TTM) | ₹2.95b |
| Revenue (TTM) | ₹15.22b |
89.5x
P/E Ratio17.3x
P/S RatioIs POLYMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| POLYMED income statement (TTM) | |
|---|---|
| Revenue | ₹15.22b |
| Cost of Revenue | ₹5.14b |
| Gross Profit | ₹10.08b |
| Other Expenses | ₹7.13b |
| Earnings | ₹2.95b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 29.10 |
| Gross Margin | 66.23% |
| Net Profit Margin | 19.37% |
| Debt/Equity Ratio | 6.1% |
How did POLYMED perform over the long term?
See historical performance and comparison